Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive body weight is global and affects over 2 billion people around the world. Due to the increasing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with accompanying risk factors. To fight obesity, however, we primarily use lifestyle modification methods, such as a rational and balanced diet based on reduced caloric content and a low-carbohydrate diet. Another aspect is the use of the optimal amount of exercise of moderate intensity. Only the combination of all these methods gives a real chance for long-term weight loss and maintenance. Scientific research on GLP-1 analogue drugs such as semaglutide and liraglutide brings us a lot of prospects. The mechanism of their action is based on mimicking the natural GLP-1 secreted in the body. Aim of the study: The following article as an analysis of the current medical knowledge on the effectiveness and safety of obesity treatment with GLP-1 agonists based on available publications. Methods and materials: Literature review based on PubMed data using the following key words: obesity; semaglutide; Glucagon-like peptide-1 (GLP-1) agonists State of knowledge: GLP-1 receptor agonists are incretin drugs. This class of drugs has been approved by the FDA for the treatment of type 2 diabetes. Results: Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of Education, Health and Sport - 13(2023), 4 |
| Sprache: |
Englisch ; Spanisch ; Polnisch ; Russisch ; Ukrainisch |
|---|
| Beteiligte Personen: |
Magdalena Mazurek [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Agoniści glukagonopodobnego peptydu-1 (GLP-1); |
|---|
| doi: |
10.12775/JEHS.2023.13.04.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ081043996 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ081043996 | ||
| 003 | DE-627 | ||
| 005 | 20230310195206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12775/JEHS.2023.13.04.022 |2 doi | |
| 035 | |a (DE-627)DOAJ081043996 | ||
| 035 | |a (DE-599)DOAJf84fb8cccf99458881aafb0f96013bf0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa |a pol |a rus |a ukr | ||
| 050 | 0 | |a GV557-1198.995 | |
| 100 | 0 | |a Magdalena Mazurek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive body weight is global and affects over 2 billion people around the world. Due to the increasing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with accompanying risk factors. To fight obesity, however, we primarily use lifestyle modification methods, such as a rational and balanced diet based on reduced caloric content and a low-carbohydrate diet. Another aspect is the use of the optimal amount of exercise of moderate intensity. Only the combination of all these methods gives a real chance for long-term weight loss and maintenance. Scientific research on GLP-1 analogue drugs such as semaglutide and liraglutide brings us a lot of prospects. The mechanism of their action is based on mimicking the natural GLP-1 secreted in the body. Aim of the study: The following article as an analysis of the current medical knowledge on the effectiveness and safety of obesity treatment with GLP-1 agonists based on available publications. Methods and materials: Literature review based on PubMed data using the following key words: obesity; semaglutide; Glucagon-like peptide-1 (GLP-1) agonists State of knowledge: GLP-1 receptor agonists are incretin drugs. This class of drugs has been approved by the FDA for the treatment of type 2 diabetes. Results: Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism. | ||
| 650 | 4 | |a obesity | |
| 650 | 4 | |a agoniści glukagonopodobnego peptydu-1 (GLP-1); | |
| 650 | 4 | |a semaglutyd | |
| 653 | 0 | |a Education | |
| 653 | 0 | |a L | |
| 653 | 0 | |a Sports | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Edyta Białowąs |e verfasserin |4 aut | |
| 700 | 0 | |a Ewelina Dybała |e verfasserin |4 aut | |
| 700 | 0 | |a Iwona Cuber |e verfasserin |4 aut | |
| 700 | 0 | |a Artur Aghadi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Education, Health and Sport |d Kazimierz Wielki University, 2017 |g 13(2023), 4 |w (DE-627)DOAJ000116637 |x 23918306 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |
| 856 | 4 | 0 | |u https://doi.org/10.12775/JEHS.2023.13.04.022 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f84fb8cccf99458881aafb0f96013bf0 |z kostenfrei |
| 856 | 4 | 0 | |u https://apcz.umk.pl/JEHS/article/view/42726 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2391-8306 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 | ||